Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain

被引:6
作者
Golbahar, Jamal [1 ,2 ]
Al-Ayadhi, Maha [2 ]
Das, Negalla Mohan [2 ]
Gumaa, Khalid [2 ]
机构
[1] AGU, Coll Med & Med Sci, Al Jawhara Ctr Genet Diag & Res, Dept Mol Med, Manama, Bahrain
[2] AGU, Coll Med & Med Sci, Dept Med Biochem, Manama, Bahrain
来源
INTERNATIONAL JOURNAL OF WOMENS HEALTH | 2012年 / 4卷
关键词
polycystic ovary syndrome; insulin resistance; gonadotrophin; hyperandrogenemia; diagnostic markers;
D O I
10.2147/IJWH.S30661
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: In women with polycystic ovary syndrome (PCOS), despite a high prevalence of insulin resistance, hyperandrogenemia, and disturbances in the secretion of gonadotrophin, the principal causes of biochemical abnormalities and the best endocrine markers for PCOS have not been fully identified. Subjects and methods: Serum levels of insulin, glucose, follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone, estrogen, sex hormone-binding capacity (SHBG), and other related indices such as homeostasis model assessment, insulin glucose ratios, LH/FSH ratios, and the free androgen index (FAI) were determined and compared in women with PCOS (n = 50) and women without PCOS (n = 50). Results: In multivariate logistic regression analyses, among all insulin resistance indices, only hyperinsulinemia (odds ratio [OR] = 2.6; confidence interval [CI]: 1.3-5.2; P = 0.008) was significantly and independently associated with PCOS when adjusted for body mass index (BMI), hyperandrogenemia, and LH/FSH ratios. The LH/FSH ratio (OR = 5.4; CI: 1.2-23.0, P = 0.03) was the only marker among those indices for inappropriate gonadotrophin secretion that significantly and independently associated with PCOS when adjusted for BMI and - hyperinsulinemia. Among those indices for hyperandrogenemia, FAI (OR = 1.1; CI: 1.0-2.7; P = 0.02) and SHBG (OR = 1.2; CI: 1.2-3.4; P = 0.03) were significantly and independently associated with PCOS when adjusted for BMI and hyperinsulinemia. In addition, receiver operating characteristic analysis showed that the best predictive markers for PCOS were insulin (area under the curve [AUC] = 0.944; CI: 0.887-0.989), FAI (AUC = 0.932; CI: 0.895-0.993), SHBG (AUC = 0.924; CI: 0.87-0.978), and LH/FSH ratios (AUC = 0.906; CI: 0.821-0.965). Conclusion: For insulin and LH/FSH ratios, FAI, and SHBG seemed the best predictors and markers for insulin resistance, inappropriate gonadotrophin secretion, and hyperandrogenemia, respectively, with high sensitivity and specificity for identifying Bahraini women with and without PCOS.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 30 条
  • [1] The prevalence and features of the polycystic ovary syndrome in an unselected population
    Azziz, R
    Woods, KS
    Reyna, R
    Key, TJ
    Knochenhauer, ES
    Yildiz, BO
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) : 2745 - 2749
  • [2] What is polycystic ovary syndrome? Are national views important?
    Balen, A
    Michelmore, K
    [J]. HUMAN REPRODUCTION, 2002, 17 (09) : 2219 - 2227
  • [3] Obesity and polycystic ovary syndrome
    Barber, T. M.
    McCarthy, M. I.
    Wass, J. A. H.
    Franks, S.
    [J]. CLINICAL ENDOCRINOLOGY, 2006, 65 (02) : 137 - 145
  • [4] Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots
    Barth, Julian H.
    Field, Helen P.
    Yasmin, Ephia
    Balen, Adam H.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 162 (03) : 611 - 615
  • [5] Motta DAB, 2008, CURR PHARM DESIGN, V14, P2121
  • [6] CORRELATION OF HYPERANDROGENISM WITH HYPERINSULINISM IN POLYCYSTIC OVARIAN DISEASE
    BURGHEN, GA
    GIVENS, JR
    KITABCHI, AE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 50 (01) : 113 - 116
  • [7] Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia
    Cho, L. W.
    Kilpatrick, S.
    Jayagopal, V.
    Diver, M. J.
    Atkin, S. L.
    [J]. CLINICAL ENDOCRINOLOGY, 2008, 68 (03) : 390 - 394
  • [8] Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients
    Ciampelli, M
    Leoni, F
    Cucinelli, F
    Mancuso, S
    Panunzi, S
    De Gaetano, A
    Lanzone, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) : 1398 - 1406
  • [9] Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies
    Escobar-Morreale, HF
    Asunción, M
    Calvo, RM
    Sancho, J
    Millán, JLS
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (05) : 619 - 624
  • [10] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
    Fauser, BCJM
    Chang, J
    Azziz, R
    Legro, R
    Dewailly, D
    Franks, S
    Tarlatzis, BC
    Fauser, B
    Balen, A
    Bouchard, P
    Dahlgren, E
    Devoto, L
    Diamanti, E
    Dunaif, A
    Filicori, M
    Homburg, R
    Ibanez, L
    Laven, J
    Magoffin, D
    Nestler, J
    Norman, RJ
    Pasquali, R
    Pugeat, M
    Strauss, J
    Tan, S
    Taylor, A
    Wild, R
    Wild, S
    Ehrmann, D
    Lobo, R
    [J]. HUMAN REPRODUCTION, 2004, 19 (01) : 41 - 47